New Tablet Strength Provides Additional Dosing Option for Erleada

Credit: Janssen.
Erleada (apalutamide), an androgen receptor inhibitor, is now available in a 240mg tablet.

Erleada® (apalutamide) is now available in a new 240mg tablet for the treatment of patients with non-metastatic castration-resistant prostate cancer, as well as for metastatic castration-sensitive prostate cancer.

Previously, Erleada was only supplied as 60mg tablets. Health care providers now have the option to prescribe Erleada as either four 60mg tablets taken once daily, or one 240mg tablet for patients who prefer to take fewer pills.

For individuals who have difficulty swallowing, the 240mg tablet can be dispersed in non-carbonated water and then administered with either orange juice, applesauce, or additional water; the 60mg tablet is only approved for mixing with applesauce. The 240mg tablet may also be administered via a feeding tube.

“Each person and their cancer are unique and, as such, there is no one-size-fits-all approach to treatment,” said Luca Dezzani, MD, Vice President, Medical Affairs, Solid Tumor, Janssen Scientific Affairs, LLC. “The availability of 240mg and 60mg strength options of Erleada demonstrates Janssen’s commitment to prostate cancer patients and provides prescribers flexibility in dosing and methods of administration to fit each patient’s unique needs.”

Erleada, an androgen receptor inhibitor, is supplied as 60mg tablets in 120-count bottles and 240mg tablets in 30-count bottles. The product is available via prescription through existing specialty pharmacy networks.


  1. Erleada® (apalutamide), first-and-only next-generation androgen receptor inhibitor with once-daily, single-tablet option now available in the US. News release. The Janssen Pharmaceutical Companies of Johnson & Johnson. Accessed April 3, 2023.
  2. Package insert. Janssen Biotech; 2023. Accessed April 3, 2023.